OrthoPediatrics Reports Record 2025 Revenue, Strong Q4 Free Cash Flow, and Positive 2026 Guidance
Summary
OrthoPediatrics Corp. announced record preliminary unaudited net revenue for full year 2025 and Q4 2025, alongside significantly reduced free cash flow usage and positive 2026 financial guidance.
Key Events
-
Record 2025 Revenue
Achieved preliminary unaudited full year 2025 net revenue of $236.1 million, representing 15% growth over 2024.
-
Strong Q4 Performance
Reported preliminary unaudited fourth quarter 2025 net revenue of $61.3 million, a 16% increase year-over-year, and generated $6.0-$7.0 million in free cash flow.
-
Improved Free Cash Flow
Total year 2025 free cash flow usage was over 50% lower than 2024, indicating enhanced operational efficiency.
-
Positive 2026 Guidance
Projected 2026 revenue in the range of $262 million to $266 million (11-13% growth) and approximately $25 million in Adjusted EBITDA.
Analysis
This 8-K filing provides a strong operational and financial update for OrthoPediatrics. The company's ability to deliver record revenue growth in 2025, significantly reduce free cash flow usage, and project continued growth with positive Adjusted EBITDA for 2026 suggests robust business momentum and improving profitability. The EUMDR certification also de-risks European market access for important product lines. Investors should view this as a positive signal regarding the company's execution and future outlook in the pediatric orthopedics market.
At the time of this filing, KIDS was trading at $18.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $469.7M. The 52-week trading range was $15.28 to $27.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.